Heart transplantation

ERBASAN O., KEMALOĞLU C., BAYEZID O.

ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.8, ss.131-147, 2008 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2008
  • Dergi Adı: ANATOLIAN JOURNAL OF CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.131-147
  • Anahtar Kelimeler: Heart transplantation, immunosuppression, rejection, cardiac allograft vasculopathy, endomyocardial biopsy, CORONARY-ARTERY-DISEASE, CARDIAC TRANSPLANTATION, MYCOPHENOLATE-MOFETIL, ACUTE REJECTION, INTERNATIONAL SOCIETY, LUNG TRANSPLANTATION, ALLOGRAFT-REJECTION, ALTERNATE LIST, RECIPIENTS, PREVENTION
  • Akdeniz Üniversitesi Adresli: Evet

Özet

End-stage heart failure is still associated with a decrease in both quality and prognosis of life and one- year survival of these patients is below 50%. Heart transplantation remains the final therapeutic option for the treatment of irreversible end-stage heart failure in all age groups with adequate success rates. Survival of patients who underwent heart transplantation has improved incrementally in recent years, with 86% survival in the first year and over 50% survival at 10 years. Approximately 50% of patients live for more than 10 years after heart transplantation and 25% of patients live for more than 18 years. Improvement of the quality of life is an other benefit, while the patients were in NYHA class III-IV preoperatively, nearly all of them have an improved functional status with NYHA class I-II after transplantation. However, discrepancy between the number of candidates and number of available donors is still the major problem for the applicability of heart transplantation. (Anadolu Kardiyol Derg 2008; 8: Suppl 2; 131-47)